Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial

  1. Home
  2. International
  3. USA
  4. Austin
  5. Business (B2B)
  6. Businesses For Sale
  1. Posted by: [email protected]
  2. Member since: June 2026
  3. Posted:
  4. Category: Businesses For Sale
  5. Region: Austin (Astin)
  6. Posting ID: 63684214
Genentech’s Phase III Krascendo 1 trial shows divarasib significantly improves progression-free survival over approved KRAS G12C inhibitors in advanced NSCLC patients.

Austin, Businesses For Sale, Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial
Back Next
Email to a Friend

Ask AI to Review This Ad

Problem with this ad?


How to Avoid Scams